Dr. Colin brings four decades of clinical experience in pediatric pulmonology to Beyond Air, with research spanning respiratory physiology, Cystic...
NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company...
Company to host virtual investor event on Sunday, December 12, 2021 at 11:00 a.m. ETSOUTH SAN FRANCISCO, Calif., Dec. 01,...
NEW YORK, NY, Dec. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”),...
Former Chief Medical Officer of Juno Therapeutics Brings Decades of Oncology Clinical Development ExpertiseNEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE)...
Renowned Expert Dr. Christopher Gauland Shares Insights on Treating DFUs and Success with AC5® Advanced Wound System FRAMINGHAM, Mass., Dec....
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which...
Modifications to Entolimod clinical trial protocol in acute radiation syndrome enable continued program developmentFORT COLLINS, Colo., Dec. 01, 2021 (GLOBE...
ATLANTA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is...
Drug overdoses are the leading cause of death for those under age 50SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) --...
Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of CancerCHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE)...
1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and...
- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into...
Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children The...
New Trial Designed to Further Investigate the Immune-Based MOA of Trilaciclib and Help Determine Future Target Tumor Types and Treatment...
PDUFA date extended by three months to April 5, 2022 No Additional Data Requested Following Meeting with FDA NEW HAVEN,...
Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 studyCAMBRIDGE, Mass., Dec. 01, 2021...
CNM-Au8 has favorable impact on progression of ALS as measured by joint rank comparison of combined survival and ALSFRS-R change...
Vancouver, B.C, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (the “Company” or “Origin Therapeutics”) an actively managed...
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated...
